Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin

Cancer Letters

Volumn 298, Issue 1, 2010, Pages 26-33

  Zhang, Xinbo ^a   Chen, Baosheng ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Anticancer; Apolipoprotein AI; Cysteine mutant; Delivery vehicle; High density lipoprotein

Indexed keywords

10 HYDROXYCAMPTOTHECIN; APOLIPOPROTEIN A1; CYSTEINE; HIGH DENSITY LIPOPROTEIN; RECOMBINANT HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; 10-HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DRUG CARRIER; DRUG VEHICLE; HYBRID PROTEIN; NANOPARTICLE;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HCT116; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG LUNG LEVEL; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SPLEEN LEVEL; DRUG TISSUE LEVEL; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SURVIVAL RATE; SUSTAINED DRUG RELEASE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; HCT116 CELL LINE; TISSUE DISTRIBUTION;

ANIMALS; APOLIPOPROTEIN A-I; CAMPTOTHECIN; CYSTEINE; DRUG CARRIERS; FEMALE; HCT116 CELLS; HUMANS; LIPOPROTEINS, HDL; MICE; MICE, INBRED BALB C; NANOPARTICLES; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; VEHICLES; PHARMACEUTICAL VEHICLES;

EID: 77956932187     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.023     Document Type: Article

References (30)

1. Jaxel C., Kohn K.W., Wani M.C., Wall M.E., Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989, 49:1465-1469.
2. Wall M.E. Camptothecin and taxol: discovery to clinic. Med. Res. Rev. 1998, 18:299-314.
3. Wang A., Li S. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect. BMC Biotechnol. 2008, 8:46.
4. Zhang L., Yang M., Wang Q., Li Y., Guo R., Jiang X., Yang C., Liu B. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Control. Release 2007, 119:153-162.
5. Sezgin Z., Yuksel N., Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur. J. Pharm. Biopharm. 2006, 64:261-268.
6. Lu J.L., Wang J.C., Zhao S.X., Liu X.Y., Zhao H., Zhang X., Zhou S.F., Zhang Q. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur. J. Pharm. Biopharm. 2008, 69:899-907.
7. Wasan K.M., Brocks D.R., Lee S.D., Sachs-Barrable K., Thornton S.J. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat. Rev. Drug Discov. 2008, 7:84-99.
8. Hamidi M., Foroozesh M., Zarrin A. Lipoproteins: from physiological roles to drug delivery potentials. Crit. Rev. Ther. Drug Carrier Syst. 2006, 23:497-523.
9. Lacko A.G., Nair M., Paranjape S., Johnso S., McConathy W.J. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002, 22:2045-2049.
10. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
11. McConathy W.J., Nair M.P., Paranjape S., Mooberry L., Lacko A.G. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008, 19:183-188.
12. Feng M., Cai Q., Huang H., Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur. J. Pharm. Biopharm. 2008, 68:688-693.
13. Oda M.N., Hargreaves P.L., Beckstead J.A., Redmond K.A., Van Antwerpen R., Ryan R.O. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J. Lipid Res. 2006, 47:260-267.
14. Sirtori C.R., Calabresi L., Franceschini G., Baldassarre D., Amato M., Johansson J., Salvetti M., Monteduro C., Zulli R., Muiesan M.L., Agabiti-Rosei E. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001, 103:1949-1954.
15. Bruckert E., von Eckardstein A., Funke H., Beucler I., Wiebusch H., Turpin G., Assmann G. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis 1997, 128:121-128.
16. Segrest J.P., Garber D.W., Brouillette C.G., Harvey S.C., Anantharamaiah G.M. The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv. Protein Chem. 1994, 45:303-369.
17. Zhu X., Wu G., Zeng W., Xue H., Chen B. Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid Res. 2005, 46:1303-1311.
18. Wang Y., Zhu X., Wu G., Shen L., Chen B. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J. Lipid Res. 2008, 49:1640-1645.
19. Williams D.L., de La Llera-Moya M., Thuahnai S.T., Lund-Katz S., Connelly M.A., Azhar S., Anantharamaiah G.M., Phillips M.C. Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic alpha-helix as a recognition motif. J. Biol. Chem. 2000, 275:18897-18904.
20. Rhainds D., Brodeur M., Lapointe J., Charpentier D., Falstrault L., Brissette L. The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters. Biochemistry 2003, 42:7527-7538.
21. Feng M., Cai Q., Shi X., Huang H., Zhou P., Guo X. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J. Drug Target. 2008, 16:502-508.
22. Weisgraber K.H., Bersot T.P., Mahley R.W., Franceschini G., Sirtori C.R. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J. Clin. Invest. 1980, 66:901-907.
23. Lacko A.G., Nair M., Paranjape S., Mooberry L., McConathy W.J. Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy 2006, 52:171-173.
24. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
25. de Smidt P.C., van Berkel T.J. LDL-mediated drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 1990, 7:99-120.
26. Muntoni S., Atzori L., Mereu R., Satta G., Macis M.D., Congia M., Tedde A., Desogus A. Serum lipoproteins and cancer. Nutr. Metab. Cardiovasc. Dis. 2009, 19:218-225.
27. Cao W.M., Murao K., Imachi H., Yu X., Abe H., Yamauchi A., Niimi M., Miyauchi A., Wong N.C., Ishida T. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004, 64:1515-1521.
28. Lacko A.G., Nair M., Prokai L., McConathy W.J. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin. Drug Deliv. 2007, 4:665-675.
29. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 2010, 18:53-58.
30. Sanchez A., Tobio M., Gonzalez L., Fabra A., Alonso M.J. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci. 2003, 18:221-229.